Study Reveals Timing of Immunotherapy Could Boost Cancer Survival

Research indicates that administering anticancer immunotherapy earlier in the day may significantly enhance survival rates for patients with cancer. A study published in the journal Cancer reveals that the timing of treatment, influenced by the body’s internal clock, could be pivotal in optimizing therapeutic outcomes.

The study involved 397 patients diagnosed with extensive-stage small cell lung cancer, who received immunotherapy drugs atezolizumab or durvalumab in conjunction with chemotherapy. This research was conducted at the Affiliated Cancer Hospital of Xiangya School of Medicine at Central South University in China, spanning from May 2019 to October 2023.

The findings suggest that patients who received treatment before 3:00 PM exhibited significantly improved outcomes. Specifically, these individuals experienced longer progression-free survival and overall survival compared to those treated later in the day. After accounting for various influencing factors, the study concluded that earlier treatment timing was associated with a 52% reduction in the risk of cancer progression and a 63% lower risk of death.

Clinical Implications of Timing Adjustments

Senior author Dr. Yongchang Zhang emphasized the potential of this research to influence clinical practices. He noted, “Adjusting infusion timing is a straightforward and easily implementable intervention that can be adopted across diverse healthcare settings without additional cost.” This suggests that implementing such timing adjustments could be a practical approach to enhancing treatment efficacy for patients battling small cell lung cancer.

The implications of these findings extend beyond theoretical discussions; they offer immediate clinical applicability. By optimizing treatment schedules based on circadian rhythms, healthcare providers may enhance the effectiveness of existing therapies, fundamentally transforming treatment protocols for this challenging cancer type.

As the study highlights the importance of timing in immunotherapy administration, it opens avenues for further research into the correlation between circadian rhythms and various cancer treatments. Understanding how the timing of drug delivery impacts patient outcomes could lead to more personalized and effective treatment strategies in oncology.

Further details on this study can be found in the article titled “Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer” published in the journal Cancer (2025). The study’s DOI is 10.1002/cncr.70126.